Latest News:

ar de elenfr it

TIF

Applications now open for TIF’s Renzo Galanello Fellowship Programme 2020

TIF‘s Renzo Galanello Fellowship Programme is back again in 2020! ...
FT-4202, FORMA’s Experimental SCD Therapy, Fares Well in Phase 1 Trial of Healthy Volunteers

FT-4202, FORMA Therapeutics’ experimental disease-modifying therapy for sickle cell disease (...
‘FAiTh – Fight Against Thalassemia Association’ presents its activities for January 2020

The ‘FAiTh – Fight Against Thalassemia’ group, a longtime member of TIF op...
FDA grants Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease & β-thalassaemia

An investigational gene therapy for Sickle Cell Disease (SCD) and β-thalassaemia, known as AR...
Chiesi Group and Apotex Inc. finalize agreement for the acquisition of Ferriprox® (Deferiprone)

Chiesi Farmaceutici and Apotex (together with its American subsidiary, ApoPharma Usa), a comp...

Highlights

TIF e-AcademyAcadémie électronique de la FITe-Academyالأكاديمية الإلكترونية للاتحاد الدولي للثلاسيمياΗλεκτρονική ΑκαδημίαTIF e-Akademie

Patient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy Programme

Clinical Trial UpdatesEssais cliniques - Mises à jourAggiornamenti sugli studi cliniciآخر مستجدات التجارب الإكلينكية Ενημερώσεις για κλινικές δοκιμέςUpdate zu klinischen Studien

Renzo Galanello FellowshipsBourses Renzo GalanelloBorsa di studio Renzo Galanelloمنحة رينزو جالانيلوΥποτροφίες Renzo GalanelloRenzo Galanello Stipendien

International Thalassaemia DayJournée Mondiale de la ThalassémieGiornata internazionale della talassemiaاليوم العالمي ’للثلاسيميا’Παγκόσμια Ημέρα ΘαλασσαιμίαςInternationaler Tag der Thalassämie

The THALIA ProjectThe THALIA ProjectThe THALIA ProjectThe THALIA ProjectThe THALIA ProjectThe THALIA Project